ArticlePharmacological reports : PR2026
Saikosaponin A, a bioactive compound from Bupleuri radix, protects dopaminergic neurons and correlates with NURR1 expression in 6-hydroxydopamine-injected hemi-Parkinsonian mouse model.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundParkinson’s disease (PD) is characterized by progressive dopaminergic neuronal loss, and current treatments are limited by their inability to prevent neurodegeneration. NURR1, a crucial transcription factor for dopaminergic neuron survival, has emerged as a promising therapeutic target. This study investigated whether Saikosaponin A (SSA), a bioactive compound from Bupleuri radix, exhibits neuroprotective effects through NURR1-mediated mechanisms in 6-hydroxydopamine (6-OHDA)-induced PD models.
methodsCell viability assays, protein expression analysis, behavioral tests, and immunohistochemistry assessed SSA effects. PC12 cells were treated with SSA (0.1–20 µM) followed by 6-OHDA (75 µM) exposure. 6-OHDA-lesioned mice received SSA (5 mg/kg, po) for 10 days. Behavioral assessment included rotarod, pole, and apomorphine-induced rotation tests. Dopaminergic neuronal protection was evaluated through tyrosine hydroxylase (TH) immunohistochemistry and NURR1 expression analysis.
resultsIn PC12 cells, SSA (10 µM) significantly restored NURR1 and tyrosine hydroxylase (TH) expressions compared to 6-OHDA group, while improving cell viability and antioxidative enzyme heme oxygenase-1 levels. SSA also enhanced cell survival signaling as evidenced by increased Bcl-2/Bax ratio. In 6-OHDA-lesioned mice, SSA treatment (5 mg/kg, po) significantly improved motor function in rotarod and pole tests, while reducing apomorphine-induced rotations. Furthermore, SSA protected TH-positive neurons in the substantia nigra and increased NURR1 expression compared to the 6-OHDA group.
conclusionsSSA demonstrates potential as a therapeutic agent for PD by modulating neuroprotective pathways associated with NURR1 expression. SSA provides dual benefits of motor function improvement and neuroprotection against dopaminergic neuronal death, representing a promising alternative to current symptomatic treatments that cannot halt disease progression.
Indexed as
Identifiers
40810766What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.